Drug, bio-affecting and body treating compositions inventions 06/06

20060140856 - Skeletal-targeted radiation to treat bone-associated pathologies: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such...

20060140857 - Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method: A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method...

20060140858 - Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s): The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds the targetable construct. The targetable construct comprises a carrier portion which comprises...

20060140859 - Imaging agents for early detection and monitoring of cardiovascular plaque: The present invention relates in part to a method of imaging cardiovascular plaque formation in a mammal comprising administering to the mammal an effective amount of 18F-2-fluorodeoxy-D-glucose and then detecting the 18F-2-fluorodeoxy-D-glucose....

20060140860 - Computational knowledge model to discover molecular causes and treatment of diabetes mellitus: In one aspect, the invention comprises a method of developing an immunosuppressant drug with reduced propensity to induce type II diabetes mellitus symptoms by assaying candidate molecular entities for binding preferentially to leukocyte isoform calcineurin and less preferentially to muscle cell isoform calcineurin. In another aspect, the invention comprises a...

20060140861 - Method for diagnosing lactose intolerance and diagnostic kit for performing the method: The method for diagnosing lactose intolerance in patients by the oral administration of defined amounts of lactose, followed by assaying metabolites of lactose, is performed in a way where the lactose administered contains 99% 13-labeled lactose, preferably from 5 to 30 mg, and after the administration of the 13C-lactose, the...

20060140862 - Fish hatching method and apparatus: The invention is a method and kit for conducting a rapid toxicity test. Methods and kits according to the invention include an animal or plant species in diapause....

20060140867 - Coated stent assembly and coating materials: A high magnetic susceptibility nanomagnetic material that may be attached to recognition molecules and other therapeutic biological materials so as to be targeted to specific biologic tissues, thereby enabling the presence of the targeted tissue to be detected under magnetic resonance imaging with much greater sensitivity. Also a stent coated...

20060140868 - Method of preparation of biomagnetic nanoparticles coated with a noble metal layer: A method for the preparation of magnetic nanoparticles coated with a noble metal is described. The method includes providing a first mixture containing a first non-polar organic solvent and uncoated magnetic nanoparticles. The first mixture is mixed with a second mixture containing a second non-polar organic solvent and ions comprising...

20060140869 - Polymeric contrast agents for use in medical imaging: A contrast agent comprising a polypeptide is provided. The polypeptide contains lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance...

20060140871 - Magnetic resonance imaging of prostate cancer: Paramagnetic or superparamagnetic nanoparticle-ligand conjugates that include a recognition ligand that interacts with a component on the surface of a prostate cancer cell. Nanoparticle-ligand conjugates of the invention may be used for magnetic resonance imaging of prostate cancer, or for treatment of tumors by targeted thermal ablation....

20060140870 - Method for assessing tumor response to cancer treatment: A method for measuring tumor response to a cancer therapy is provided. The method comprises the steps of injecting a polymeric contrast agent in a subject; obtaining a series of magnetic resonance image signals of the contrast agent in the tumor for up to about 60 minutes; and determining a...

20060140866 - Agents for treating neurodegenerative disorders: m

20060140865 - Nano-micelle carrier used in near infrared image detection and detection method thereof: A nano-micelle carrier used in near infrared image detection. The carrier includes a nano-micelle comprising a plurality of block copolymers having critical micelle concentration (CMC) and a near infrared dye grafted onto the micelle surface, wherein the carrier has a hydrophobic interior and a hydrophilic surface. The invention also provides...

20060140864 - Oral contrast and method of producing the oral contrast: Oral contrast compositions are used as an aid for CAT scans and are ideally fast-flowing and good tasting for assisting in quick preparation of a patient in today's extremely active and busy emergency rooms. An oral contrast used for CAT scans of the esophagus, stomach, duodenum, jejunum, small intestines, colon...

20060140863 - Production of a dye agent for colouring cells in the human or animal body: Use of a biocompatible dye, for example patent blue V or brilliant blue R, for the production of a dye agent for non-cytotoxic visualisation of cells, in particular delimiting or separating membranes in the human or animal body, in particular in the eye....

20060140873 - Aerosol pharmaceutical compositions: A suspension aerosol composition suitable for use in pressurized metered dose inhalers has improved post-shaking suspension stability and comprises predetermined amounts of an active pharmaceutical ingredient (API) insoluble in the composition, a propellant comprising a hydrofluoroalkane (HFA), and a pharmaceutically acceptable non-aminated C1-6 organic acid....

20060140872 - Novel signaling pathway for the production of inglammatory pain and neuropathy: This invention relates to a remedy for treating allergic contact dermatitis containing a substance having MEK inhibitory action as its effective component....

20060140875 - Semi-soft c-class immunostimulatory oligonucleotides: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C....

20060140874 - Stable aerosol formulations of peptides and protein with non-cfc propellants: Glycosidicaily stabilised macromolecules, such as proteins and peptides, have substantially greater stability in the presence of hydrofluoroalkane propellants for dispensing from metered dose inhalers, when formulated with polyhydroxylated polyalkenes such as PVA....

20060140876 - Buccal cavity treatment composition and corresponding uses thereof: Composition for treatment of the oral cavity and corresponding uses. The composition comprises the combination of a chlorhexidine derivative, for example chlorhexidine digluconate, with triclosan and a zinc salt, for example zinc lactate or citrate. Preferably the chlorhexidine digluconate is present in a concentration of between 0.01 and 0.2%, the...

20060140878 - Classified silica for improved cleaning and abrasion in dentifrices: A method of making precipitated silica abrasive compositions having excellent cleaning performance and lower abrasiveness with post-reactor sizing of the abrasive particles being performed via air classification techniques is provided. By targeting a specific particle size range, it has been determined that higher pellicle film cleaning levels may be achieved...

20060140877 - Methods of producing improved cleaning abrasives for dentifrices: A method of making precipitated silica abrasive compositions having excellent cleaning performance and lower abrasiveness with post-reactor sizing of the abrasive particles being performed via air classification techniques is provided. By targeting a specific particle size range, it has been determined that higher pellicle film cleaning levels may be achieved...

20060140881 - Oral care compositions containing flavonoids and flavans: Oral care compositions containing: a free-B-ring flavonoid and a flavan; as well as at least one bioavailability-enhancing agent are provided. Methods of using the oral compositions are also provided....

20060140880 - Oral compositions containing biphenol antibacterial compounds: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I)....

20060140879 - Two phase toothpaste composition: An oral care composition having a first phase of clinically efficacious 2,4,4′-trichloro 2′-hydroxydiphenyl ether admixed in a first orally acceptable aqueous vehicle, and a second phase having a stannous salt (such as stannous fluoride) admixed in a second orally acceptable aqueous vehicle. The second phase has no less than 10...

20060140882 - Two phase whitening oral care composition: An oral care (toothpaste) amalgam composition has first and second aqueous phases. The first phase has a measured pH of from about 7 to about 9 and contains 2,4,4′-trichloro-2′-hydroxydiphenyl ether and a methylvinyl ether-maleic anhydride copolymer antibacterial-enhancing agent for the ether. The second aqueous phase has a measured pH of...

20060140885 - Method of reducing oral tissue inflammation using magnolia extract: A method for treating a mammal having oral tissue inflammation is provided, where the inflamed oral tissue is contacted with a safe, efficacious, non-irritating oral composition having an anti-inflammatory agent comprising a magnolia extract. The magnolia anti-inflammatory active ingredient reduces one or more mediators of inflammation and reduces inflammation in...

20060140883 - Oral care compositions containing a eucalyptus extract: Oral care compositions comprising an antibacterial effective amount of an antibacterial system comprising a substantially water insoluble, noncationic antibacterial agent and Eucalyptus extract and an orally acceptable carrier. Methods of inhibiting oral bacteria in the oral cavity of a human or other animal subject are also provided....

20060140884 - Oregano oral care compositions and methods of use thereof: A multi-benefit oral composition is provided. The oral composition is efficacious as an antibacterial, antiplaque, anti-inflammatory, anti-oxidant, and anti-halitosis oral composition. The active ingredient has one or more active compounds from an extract of oregano. The oral composition can be in the form of a mouth rinse; a dentifrice, including...

20060140887 - Hair conditioning composition: The present invention is related to a conditioning composition for hair comprising flavone derivatives and particularly on enhanced deposition of flavone derivatives onto hair. Accordingly, the compositions comprise at least one conditioning agent, at least one organic solvent, at least one flavone derivative and at least one hydroxycarboxylic and/or dicarboxylic...

20060140886 - Tanning aids: The invention relates to tanning aids comprising a polymethylmethacrylate moulded body, which contains between 0.1 and 1.5 wt. % of a UV-stabiliser comprising a 2,2,6,6 tetraalkyl piperidyl group, said stabiliser having a transmission of at least 95% when dissolved in MMA with a concentration of 1 wt. % at 330...

20060140888 - Whitening agent containing crystalline molecular complex of hydroquinone and surfactant: There are provided a hydroquinone-containing whitening agent having high storage stability and sustained release of hydroquinone, a process for production of the whitening agent, and a whitening method for skin which employs the whitening agent. The whitening agent of the invention comprises a crystalline molecular complex composed of hydroquinone or...

20060140889 - Affinity proteins for controlled application of cosmetic substances: Provided are means and methods for applying a cosmetic substance to a desired target. The method comprises providing a conjugate of a proteinaceous substance having a specific affinity for the target molecule linked to a cosmetic substance, whereby the resulting connection between the cosmetic substance and the target molecule can...

20060140890 - Oily solid cosmetic and method for production thereof: An oil-based solid cosmetic comprising (A) vitamin A and/or a fatty acid ester thereof, (B) silicic anhydride, (C) an oil-soluble antioxidant, and (D) an oily ingredient existing as paste and/or liquid at room temperature is disclosed. The aforementioned oil-based solid cosmetic, wherein the ingredient (B) is aerosol silicic anhydride, and...

20060140891 - Cosmetic composition: The invention provides a cosmetic composition, particularly a cosmetic composition for antiperspiration. The invention relates to a cosmetic composition comprising surface-hydrophobated water-absorbing polymer particles and an anti-perspiring component, as well as a cosmetic composition comprising water-absorbing polymer particles, an anti-perspiring component, and at least one member selected from the group...

20060140896 - Cosmetic compositions comprising at least one silicone copolymer in a aqueous emulsion and at least one thickener, and uses thereof: Cosmetic compositions comprising, in a cosmetically acceptable medium, at least one aqueous emulsion of at least one silicone copolymer with a dynamic viscosity ranging from 1×106 to 100×106 cP and at least one non-cellulose thickener. This combination can give cosmetic properties, such as at least one of smoothness, lightness, and...

20060140894 - Olefin wax, silicone-modified olefin waxes, silicone-base cold-setting compositions made by using the same, and cosmetics containing the same: An olefin wax (A) is (i) a copolymer (A1) obtained by copolymerizing ethylene and at least one diene or a copolymer (A2) obtained by copolymerizing ethylene, at least one olefin selected from α-olefins of 3 to 12 carbon atoms and at least one diene; wherein (ii) the content of unsaturated...

20060140895 - Two-part cosmetic product: There are provided two-part cosmetic products and methods for imparting a filling and swelling effect to skin, lips, hair, eyelashes, and/or eyebrows. The two-part cosmetic product has an anhydrous liquid or semi-solid first part composition with a water absorbent polymer, and a water-based second part composition with a water soluble...

20060140900 - Method for enhancing chroma of hair: There is provided a method for enhancing a chroma of hair which comprises the steps of shampooing the hair with a water-based shampoo containing (A) 5 to 20% by weight of an anionic surfactant, (B) 0.1 to 5% by weight of a water-insoluble modified silicone containing at least one of...

20060140897 - Biphasic inducing agent for aqueous cleansing compositions: The invention relates to the use of specifically defined agents that induce the formation of biphasic liquid cleansing compositions. In particular the biphasic inducing agents include water soluble, high-gel-point polysaccharides having a molecular weight greater than about 10,000 Daltons; fatty ester or fatty ether ethoxylates of intermediate ethoxylation; and mixtures...

20060140898 - Use of a combination of at least one associated polymer and at least one amphiphilic diblock copolymer for thickening cosmetic compositions: at least one associative polymer comprising at least one hydrophilic part and at least one C8-40 fatty chain, and at least one linear diblock block copolymer composed of a hydrophobic block and a hydrophilic block, with the proviso that the at least one linear diblock block copolymer is not chosen...

20060140893 - Assay of hair proteins: A process for detecting previous treatment of keratinous fibers with alkaline technology for hair straightening or smoothing includes: bringing the keratinous fibers into contact with an extraction solution under conditions effective to cause dissolution of keratin proteins; and conducting a qualitative and/or quantitative assay of the keratin proteins dissolved in...

20060140892 - Method for generation of memory effects on hair: Disclosed is a method for achieving a recallable hair deformation. A composition is applied onto hair, comprising at least one active agent, which, alone or in combination with further compounds, is able, after application to the hair and after carrying out the treatment of hair in accordance with the present...

20060140899 - Skin cleansing system comprising an anti-adherent formulation and a cationic compound: Cleansing systems and methods are disclosed for improving the cleaning of skin. The cleansing systems comprise a first product comprising an anti-adherent formulation and a second product comprising a cationic compound capable of binding contaminants located on the skin. The first product is wiped across the skin of a user...

20060140901 - Articles: An article for sequential dispensing of vapours, notably evaporable fragrances, comprises separated first and second liquids (22, 24). Liquid (22) issues first. Its evaporation may be assisted by a wick (26). The simultaneous evaporation of the second liquid is prevented by an intermediate liquid phase (20). As liquid (22) issues...

20060140902 - Odor control substrates: An odor control substrate that contains a plurality of fibers oriented in the z-direction is provided. At least some of the fibers contain portions that are exposed on an outer surface of the substrate. An odor control coating is applied to the substrate so that a majority of the coating...

20060140903 - Diagnoses and treatment of disorders using an alternative glucose pathway: This invention proposes the existence of an alternate glucose pathway different from that presently accepted and offers different methods of proving this. The proposed alternate glucose pathway considers the cerebral spinal fluid as a major component of the pathway. Based on this, a diagnostic tool for detecting mental disorders and...

20060140904 - Random alkylene oxide copolymers for medical and surgical utilities: Medical and surgical uses for random alkylene oxide copolymers have been discovered. Preferably, this is a biocompatible, non-metabolizable, non-toxic, and/or readily eliminated compound that has a viscosity which is adjustable for different utilities (e.g., from runny oil to thick grease). It is also preferable to formulate the compound as an...

20060140905 - Chemokine beta-7 variants: The present invention relates to deletion and substitution mutant polypeptides of human chemokine β-7 (Ckβ-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ckβ-7,...

20060140906 - Composition comprising cysteamine for improving immunity of animals: There is provided a new use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving immunity of animals....

20060140907 - Central airway administration for systemic delivery of therapeutics: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of...

20060140909 - Method of using adenoviral vectors with increased persistence in vivo: The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours...

20060140908 - Methods for inducing an immune response via oral administration of an adenovirus: The present invention provides a method for inducing an immune response to an adenovirus in a subject which has been pre-exposed to an adenovirus or adenoviral vector. The invention further provides a method for inducing a mucosal immune response to an antigen. The methods of the invention are carried out...

20060140910 - Recombinant adenoviral vectors and methods of use: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060140920 - Adenoviral vectors encoding an antibody fused to a cd4 extracellular domain: Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector for the expression of one...

20060140921 - Disimmortalizable mammalian chromaffin cell lines for cell therapy for pain: Cloned disimmortalizable mammalian chromaffin cell lines that express chromaffin cell phenotype/genotype are disclosed....

20060140922 - Universal gm-csf expressing bystander human k562 cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition....

20060140911 - Bacteriophage for the treatment of bacterial biofilms: The present invention provides a composition for treating a bacterial biofilm, comprising a first bacteriophage that is capable of infecting a bacterium within said biofilm, and a first polysaccharide lyase enzyme that is capable of degrading a polysaccharide within said biofilm. The composition preferably further comprises a pharmaceutically-acceptable antimicrobial agent,...

20060140918 - Bioartificial device for propagation of tissue, preparation and uses thereof: The present invention relates to a device and corresponding methods for its use, in the propagation of tissue. The device comprises a bioartificial composite comprised of a substrate having at least one surface capable of the reception and growth promoting retention of a cellular preparation, and a first layer of...

20060140917 - Compositions and methods for selective dissolution of nascent intravascular blood clots: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell...

20060140916 - Methods and compositions for treating congestive heart failure: Compositions and methods for treating congestive heart failure are provided herein....

20060140912 - Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients: This invention provides a method of achieving a higher rate of allogeneic hematopoietic stem cell engraftment by either (i) matching the major histocompatibility complex class I K locus between donors and recipients or (ii) identifying how class I K on HSC interact with FC (CD8/33Kd receptor complex) works thus allowing...

20060140919 - Methods for selectively stimulating proliferation of t cells: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors...

20060140913 - Regeneration initiating cells: Methods and compositions for treating hyperglycemia and pancreatic damage as well as stimulating the repair or regeneration of islet cells are disclosed....

20060140914 - Repairing or replacing tissues or organs: In general, this invention provides methods and compositions for stabilizing, repairing, or replacing damaged or diseased tissues or organs by engineering blood vessels in such tissues or organs. In addition, the invention further provides methods and compositions for producing functional microvascular networks useful in tissue engineering....

20060140915 - Veterinary protocol for cellular regeneration: A medicament and corresponding treatment protocol for in-vivo cellular regeneration within a mammal is described. Applications include the treatment of injuries to bone, cartilage, ligaments and tendons in humans and animals. Treatment includes the step of administering one or more therapeutically effective doses of medicament into an injured, living mammal....

20060140923 - Semi-synthetic platelet gel and method for the preparation thereof: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of...

20060140924 - Composition and wipe for reducing viscosity of viscoelastic bodily fluids: The present invention provides a topical composition for application to the perianal and/or labial areas of the skin which helps prevent viscoelastic fluids, such as menses and feces, from attaching to the skin and aids in the reducing the viscoelastic properties of the fluid so that the fluid can flow...

20060140925 - Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use: A composition of biochemical compounds involved in bioenergy metabolism of cells and a method of use in prevention and therapy of diseases are disclosed....

20060140926 - Mss4 as an antifungal target: The invention provides 1-phosphotidylinositol-4-phosphate 5-kinase (MSS4) as a novel antifungal target, screening methods for MSS4 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine....

20060140927 - Cytochrome p450 enzyme complexes and methods of treatment using the same: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture....

20060140928 - Use of heparinases to decrease inflammatory response: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized...

20060140929 - Modified hirudin proteins and t-cell epitopes in hirudin: The invention concerns hirudin and in particular modified forms of hirudin with improved properties. The improved proteins contain amino acid substitutions at specific positions. The invention provides modified hirudin with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in...

20060140930 - Promotion of central nervous system remyelination using monoclonal autoantibodies: Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ autoreactivity, and recognize both surface and cytoplasmic determinants on glial cells....

20060140937 - B7-related nucleic acids and polypeptides useful for immunomodulation: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated...

20060140931 - Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment: The invention provides a bispecific molecule comprising an antibody that binds a C3b-like to one or more antigen-binding antibody fragments, each of which binds an antigenic molecule. The invention also provides methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules. The invention further provides bispecific...

20060140933 - Compositions and methods for treating rage-associated disorders: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins...

20060140932 - Human il-1 beta antagonists: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis,...

20060140936 - Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer: Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a...

20060140934 - Modified fc molecules: The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest;...

20060140935 - Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof: The present invention provides compositions and methods for treating or preventing vascular-associated disorders....

20060140940 - Anti-hgf-r antibodies and their use: The present invention relates to monoclonal antibodies which recognize the chain of the HFG receptor with the agonist activity of the natural ligand. The invention also relates to the hybridoma which secretes said antibodies and to their therapeutic and diagnostic use....

20060140941 - Growth differentiation factor-3: Growth Differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences....

20060140942 - Human g-protein coupled receptor (hetgq23): Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat...

20060140939 - Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury: A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair....

20060140938 - Monoclonal antibody specific for ppar gamma, hybridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same: The present invention relates to a hybridoma cell line producing a PPAR gamma-specific monoclonal antibody, and a method for detecting a PPAR gamma ligand related to the progression of difficult diseases, such as cancer, inflammation and metabolic diseases obesity and diabetes), using the PPAR gamma-specific monoclonal antibody. This PPAR gamma-specific...

20060140943 - Immunotherapy using modulators of notch signalling: There is provided a use of a modulator of Notch signalling for the preparation of a medicament for treatment of Graft Versus Host Disease (GVHD) and diseases and conditions caused by or associated with transplants such as organ, tissue and/or cell transplants (e.g. bone marrow transplants), wherein the modulator is...

20060140944 - Novel polypeptides involved in immune response: Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders....

20060140946 - Anti-tnf chimeric antibody fragments: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays...

20060140948 - Fully human monoclonal antibodies to il-13: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding...

20060140949 - Human anti-tnf antibodies and peptides: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060140947 - Method for treating diseases associated with abnormal kinase activity: Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced...

20060140945 - Nephropathy-associated gene: A nephropathy-associated gene which encodes a transcription repressor; and a nonhuman transgenic animal suffering from nephropathy which is constructed by transferring the above gene and allows the observation of increases in urinary volume, urinary albumin and urinary NAG, pyelectasis, enlargement in kidney tubule and glomerular swelling at the early stage...

20060140951 - Tumour necrosis factor binding ligands: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues His73-Val74-Leu75-Leu76-Thr77-His78-Thr79-Ile80-Ser81-Arg82-Ile83-Ala84-Val85-Ser86-Tyr87-Gln88-Thr89-Lys90-Val91-Asn92-Leu93-Leu94 (peptide 309) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 73-94. Antibodies or fragments...

20060140952 - Tumour necrosis factor binding ligands: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Ala22-Glu23-Gly24-Gln25-Leu26-Gln27-Trp28-Leu29-Asn30-Arg31-Arg32-Ala33-Asn34-Ala35-Leu36-Leu37-Ala38-Asn39-Gly40 (peptide 307) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 22-40. Antibodies or fragments...

20060140950 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for inflammatory and autoimmune disorders of the central nervous system and gastrointestinal tract. Also provided are methods of diagnosis....

20060140954 - Novel human protein kinases and protein kinase-like enzymes: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and...

20060140953 - Systems and methods for treating human inflammatory and proliferative diseases and wounds, with ucp and/or fas antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination...

20060140955 - Specific isotype antibodies of secretion-excretion anti-antigens of leishmania sp of promastigote or amastigote forms used as protection, resistance and curing markers of mammals to leishmaniases and to intracellular pathogenic micro-organism infections,: The invention concerns immunoglobulins characterized in that they include immunoglobulins of IgG2 classes and corresponding sub-classes, specific of secretion-excretion antigens of the prosmatigote and asmatigote forms of Leishmania sp, capable of lyzing Leishmania sp amastigotes and promastigotes in vitro, and neutralizing their proliferation....

20060140960 - Biomarkers for pre-selection of patients for anti-igf1r therapy: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small...

20060140962 - Combination treatment of pancreatic cancer: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth....

20060140961 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same....

20060140963 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The...

20060140957 - Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis: Methods and compositions for modulating ephrin/Eph receptor-mediated cell adhesion and/or cell repulsion are provided, particularly in relation to preventing, inhibiting or delaying tumour cell metastasis through modulation of Eph receptor-ephrin binding interactions and subsequent Eph receptor signalling. Particular agents useful according to the invention are agents which interfere with a...

20060140956 - Method and compounds for inhibiting hec1 ativity for the treatment of proliferative diseases: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity....

20060140959 - Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof: The present invention relates to the old-35 gene, its encoded protein, and its promoter sequence. The old-35 gene is associated with terminal differentiation and senescence of cells, and as such the gene and its related molecules may be used in the control of cell proliferation and in the modulation...

20060140958 - Tag-1 and tag-2 proteins and uses thereof: The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of...

20060140964 - Human igm antibody lysing activated lymphocytes under mediation by homologous complement: A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM...

20060140969 - Hypoallergenic polypeptides based on fish parvalbumin: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination....

20060140966 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins: The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The...

20060140965 - Immunogenic compositions comprising a xenogenic prostate protein p501s: The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for...

20060140967 - Immunogenic peptides for the treatment of prostate and breast cancer: Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1....

20060140968 - Novel tumor antigen protein sart-3 and tumor antigen peptides thereof: A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided....

20060140970 - Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis: This invention encompasses proteic binding partners of Translationally Controlled Tumor Protein (TCTP), which can modulate tumor reversion or cell apoptosis. Methods of screening for compounds useful for treating, preventing or managing cancer, an inflammatory disorder, or a neurodegenerative disorder and use of these compounds are also encompassed....

20060140971 - Cell surface expression vector of sars virus antigen and microorganisms transformed thereby: The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and...

20060140972 - Staphylococcus saprophyticus nucleic acids and polypeptides: Isolated nucleic acid molecules which encode proteins from Staphylococcus saprophyticus are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated proteins, mutated proteins, fusion proteins, antigenic...

20060140974 - Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract: A yeast extract or yeast-derived bioactive peptide having an activity of selectively inhibiting reuptake of serotonin and norepinephrine, which can be effectively used in preventing or treating various diseases related to reuptake of serotonin and norepinephrine, especially depression, anxiety, stress, fatigue and obesity are provided. Also, a yeast extract or...

20060140973 - Method for treating weight loss in patients suffering from inflammatory bowel diseases: The present invention relates to a method of treating or preventing weight loss of patients with inflammatory bowel diseases comprising administering to said patients an effective amount of Saccharomyces boulardii....

20060140975 - Regulated bacterial lysis for gene vaccine vector delivery and antigen release: The present invention generally relates to regulated host-vector systems for delivery of genetic vaccine vector or desired gene products to a eukaryotic host, preparations of bacterial genetic vaccines, genetically engineered microorganisms that are useful for delivery of genetic vaccine vectors or desired gene products, and methods of use for the...

20060140976 - Trivalent vaccine with material antibody transfer via the milk: Embodiments of the present invention generally relate to novel multivalent vaccines and methods of vaccinating. In an embodiment, the present invention is a trivalent vaccine for canine herpesvirus (CHV), canine rotavirus (CRV), and Minute virus of canine (MVC) or other canine parvovirus delivered to pups of a whelp through colustrums...

20060140977 - Methods for assaying inhibition of hiv-1 envelope glycoprotein-mediated membrane fusion: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T...

20060140978 - Genetic constructs and compositions comprising pre and cte and uses thereof: Genetic constructs that comprise a coding sequence for HIV-1 Rev, and a coding sequence for a desired protein are disclosed. Compositions that comprise at least two nucleic acid molecules in which at least one nucleic acid molecule comprises a coding sequence for HIV-1 Rev, and at least one nucleic acid...

20060140979 - Antigenic polypeptides: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides....

20060140980 - Immunization of non-human mammals against streptococcus equi: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against...

20060140981 - Intranasal delivery of pneumococcal polysaccharide vaccines: The invention relates to a method for preventing against diseases induced by Streptococcus pneumoniae infections, which comprises mucosally administering to a patient in need of a S. pneumoniae capsular polysaccharide. This latter may be conjugated or not and is preferably mixed with a mucosal adjuvant such as cholera toxin, E....

20060140982 - Tuberculosis nucleic acids, polypeptides and immunogenic compositions: The present invention provides transcriptionally active Mtb polynucleotides, recombinant Mtb peptides and polypeptides, and immunogenic Mtb antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides diagnostic kits for Mtb....

20060140983 - Dendritic cells loaded with heat shocked melanoma cell bodies: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells....

20060140986 - Anesthetic composition for topical administration: It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase;...

20060140987 - Aqueous compositions with poorly water soluble compounds: There is provided an aqueous composition comprising at least one poorly water soluble compound and at least one pH-sensitive dispersed polymer. Also provided is a method of preparing an aqueous composition, comprising the step of preparing a mixture by mixing such ingredients, where the viscosity of the mixture is less...

20060140990 - Composition for topical treatment of mixed vaginal infections: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for...

20060140984 - Cosmetic and pharmaceutical foam: The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable...

20060140985 - Lansoprazole formulations and related processes and methods: The invention provides novel liquid lansoprazole formulations comprising lansoprazole and an excipient system, wherein: (a) the concentration of lansoprazole in the formulations ranges from about 0.3 mg/mL to about 50 mg/mL; (b) the excipient system comprises either a single excipient, or a combination of two to four compositionally distinct excipients;...

20060140989 - Pharmaceutical formulations: New and improved antihistaminic syrups are disclosed....

20060140991 - Pharmaceutical preparations having an improved solubility: The present invention provides a method for producing a pharmaceutical preparation having an improved solubility, which comprises the steps of forming a micelle by dissolving a poorly-soluble drug having the ability to form the micelle into water; and fixing the micelle structure which is formed with the poorly-soluble drug, by...

20060140988 - Visco-supplement composition and methods: The present invention relates to methods and depot emulsion compositions for delivery of visco-supplements....

20060140992 - Cosmetics excellent in texture and oil-dispersibility: A cosmetic material with an excellent feeling which contains a crosslinked product of poly-γ-glutamic acid and/or a crosslinked product of a poly-γ-glutamic acid salt having a particle size of 0.1 to 100 μm and an average particle size of 1 to 50 μm, exhibits a less stickiness upon use, a...

20060140993 - Hair and scalp ointment: Abies Balsamea Resin, Beeswax, Carmel Color, Cetyl Alcohol, Disodium Edta, DMDH Hydantoin, Fragrance, Gelatin/Keratin Amino Acids/Lysine Hydroxypropyltrimonium Chloride, Glycerin, Stearate, Propylene Glyco and Imidazolidinyl Urean and Methyl Paraben and Propyl Paraben, Hydrolyzed Collagen, Microcrystalline Wax, Octoxynol-9, Panthenol (Pro Vitamin B5), Petrolatum, Propylene, Sodium Salt of Carbomer 940, Vitamin A, Vitamin...

20060140994 - Application of an antimicrobial agent on an elastomeric article: An elastomeric article having reducing microbe affinity and transmission and methods for applying and immobilizing antimicrobial compounds to the elastomeric substrate surface are disclosed. The elastomeric article has a body formed of a natural or synthetic polymer latex having an outer surface and an inner surface. The body has a...

20060140998 - Agricultural disinfectant composition:

20060140997 - Avermectin and avermectin monosaccharide derivatives substituted in the 4\"-or 4'-position having pesticidal properties: What is described are a compound of the formula (I) Wherein U is —N(R2)OR3 or —N+(O−)═C(RE)RZ); n is 0 or 1; X—Y is —CH═CH— or —CH2—CH2—; R1 is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 are, for example; independently from each other, -Q, —C(═O)-Z-Q or —CN; RZ and RE are,...

20060140995 - Methods for treating ectoparasite infections on the mammalian body: Methods for treating ectoparasites, their nymphs, and their egg infestations on animal skin and hair, wherein the compositions used in the methods contain at least one monohydric aralkyl alcohol in a quantity sufficient to provide pesticidal activity; the compositions are applied to the infected areas in a quantity sufficient to...

20060140996 - Vermin-repellant compositions and compounds: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and...

20060141003 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building...

20060141002 - Coated implants and methods of coating: A method including forming a first coating layer derived from an alkoxide on a substrate having a dimension suitable for an implant and forming a second coating layer on the first coating layer that promotes osseointegration. An apparatus comprising a substrate having a dimension suitable as a medical or dental...

20060141001 - Pharmaceutical product: A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single...

20060141000 - Porous biodegradable polymeric materials for cell transplantation: Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted...

20060140999 - Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect: The present invention relates to drug release systems which employ shape memory materials....

20060141004 - Compositions and medical devices utilizing bioabsorbable polymeric waxes: The present invention is directed to medical devices, pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about...

20060141005 - Compositions and medical devices utilizing bioabsorbable polymeric waxes: The present invention is directed to medical devices, pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about...

20060141006 - Methods and apparatus for treatment of aneurysmal tissue: The present invention encompasses methods and apparatus for aiding aneurysm repair....

20060141007 - Agent with a retarded release of substances: The present invention relates to a composition for producing a satiation effect and for weight reduction comprising at least one compound which is swellable and comprises nutrients....

20060141008 - Over-coated product including consumable center and medicament: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes one or more coatings having a medicament or agent. The coatings can further comprise one or more fat-based confectioneries to provide a coated product that...

20060141010 - Coated preparations that contain at least one hydroformate: t

20060141011 - Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health: This invention is directed to compositions for animal consumption (including foods, treats, etc.), particularly compositions that tend to improve kidney function, and particularly compositions that comprise enhanced antioxidants and reduced quantities of protein and/or phosphorus. This invention also is directed generally to methods for using such compositions....

20060141013 - Lysine mixture and apparatus and method for administering lysine: A mixture is described comprising L-lysine and a base substance palatable to cats. Also described is a improved method and apparatus for administering L-lysine using an oral syringe....

20060141009 - Novel compositions and processes for delivering an additive: Embodiments of the present invention generally relate to novel compositions and processes for the delivery of an additive to an organism in a form suitable for consumption....

20060141012 - Tissue scaffold: A tissue scaffold includes a first film having a plurality of cell openings and a second film adjacent the first film and having a plurality of cell openings larger than the cell openings of the first film. The cell openings of the first film interconnect with the cell openings of...

20060141015 - Antimicrobial material: The present invention relates to an antimicrobial material comprising sheet of fabric and- metallic salt crystals embedded in an adhesive material covering the sheet of fabric....

20060141014 - Skin treatment articles and methods: The present invention relates to skin treatment articles, particularly cleansing articles, and methods for delivering multiple skin treatment formulations to the skin....

20060141016 - Enzyme inhibiting adhesives: An adhesive composition including an adhesive component and an enzyme inhibiting component for use in ostomy and wound care applications. The enzyme inhibitors are derived from tubers, such as potatoes. In ostomy, the adhesive composition helps to secure the collection bag or pouch to the skin. In wound care application,...

20060141018 - Hemostatic compositions and methods for controlling bleeding: The invention provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions typically include an article containing cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose, or a polysaccharide ionically cross-linked and in association with the article. Methods of making and using...

20060141017 - Zinc-based compositions and methods of use: The invention relates generally to zinc-based compositions for topical use in humans and animals, and methods therefor. The invention further relates to the use of zinc-based compositions in wound treatment, cleaning and other therapeutic applications....

20060141019 - Liposome: The present invention provides a liposome to which a polyalkylene glycol and albumin are bonded having an excellent retention in blood....

20060141020 - Liposomes containing oligonucleotides: It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5′-GTGCTCCATTGATGC-3′ (SEQ. ID. NO: 1) wherein only the end bases are phosphorothioated is a preferred embodiment. Antisense sequences of up to 40 bases which contain this sequence, such as 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ...

20060141021 - Polymeric microspheres and method for preparing the same: A polymeric microsphere. The polymeric microsphere comprises a first polymer, a layer formed on the surface of the first polymer, and a second polymer formed on the layer. The invention also provides a method for preparing the polymeric microphere by an aqueous-two-phase emulsion process....

20060141026 - Imprinted paintball and apparatus and method for manufacturing same: A gel capsule has embossed surface configurations that form, in relief, an imprinted design over the entire extent of its exterior surface. An apparatus and method for producing and/or manufacturing an imprinted gel ribbon that is useful in forming the gel capsule. The apparatus includes a spreader box and a...

20060141025 - Methods and compositions for delivery of catecholic butanes for treatment of tumors: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such...

20060141023 - Pharmaceutical compositions containing abiguanide-glitazone combination: The present invention relates to an orally administered pharmaceutical composition that is a combination of two or more antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agent is present in an immediate release form....

20060141022 - Soft capsule preparation: A soft capsule preparation which comprises a dispersion of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid in a vegetable oil filled in a soft capsule comprising a shell having a light blocking effect. The soft capsule preparation preferably comprises polyoxyethylene sorbitan monooleate and glycerol monostearate and the like as surfactants. As the vegetable oil, soybean...

20060141024 - Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria: The present invention relates to a method for preparation of synergistic combination kits of α,β-arteether, sulfadoxin and pyrimethamine for the treatment of severe/multi-drug resistant cerebral malaria....

20060141028 - Cyclosporin formulations: The present invention relates to compositions comprising solutions of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compositions....

20060141030 - Method and composition for stable and controlled delivery of (-)-hydroxycitric acid: The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable...

20060141029 - Methods and compositions for delivery of catecholic butanes for treatment of diseases: The present invention provides kits, methods and compositions for the treatment of diseases, such as, for example, non-cancer proliferative diseases, neurodegenerative diseases, diabetes and hypertension. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA Compounds in a pharmaceutically acceptable carrier or...

20060141031 - Orally disintegrating pharmaceutical compositions with sensory cue agents: The present invention relates to pharmaceutical compositions that disintegrate in the mouth and include at least one systemically active pharmaceutical ingredient in a therapeutically effective amount and at least one sensory cue agent in a sensory effective amount....

20060141027 - Sublingual administration of non-steroidal anti-inflammatory pharmacological substances: The present invention relates to a sublingual administration method of non-steroidal ant-inflammatory, referred as FANS, which allows to considerably reduce the therapeutic dose, with the additional advantage of increasing the quickness of the effects and improving the tolerability....

20060141032 - Effervescent formulations comprising apomorphine: An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine....

20060141034 - Gaba analog prodrug sustained release oral dosage forms: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective....

20060141035 - Hmg-coa reductase inhibitor extended release formulation: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug...

20060141036 - Hmg-coa reductase inhibitor extended release formulation: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug...

20060141033 - P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient: The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceding...

20060141037 - Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof: Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to...

20060141038 - Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof: The present invention describes how to obtain composite products comprising an active substance supported by a carrier, in which the carrier is the linear copolymer of N-vinyl-2-pyrrolidone with vinyl acetate. The composite products are obtained by co-grinding of the dry mixture of the active substance and of the aforesaid carrier....

20060141040 - Injectable non-aqueous suspension: The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions....

20060141039 - Oral compositions containing oxidized camellia: Oral composition comprising a Camellia extract of semi-oxidized tissue from a member of the genus Camellia and an enhancing agent....

20060141048 - (polyalkoxy)sulfonate surface modifiers: The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised...

20060141043 - Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides: e

20060141050 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141051 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141052 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141042 - Hollow nanoparticle having modified cysteine residue and drug with the use thereof: The invention provides hollow nanoparticles of a protein with the ability to recognize specific cells such as the hepatocytes and to form particles (for example, hepatitis B virus surface-antigen protein), wherein the protein has a cysteine residue substituted to a different amino acid. The hollow nanoparticles have a stable particle...

20060141045 - Isolation of cells or the like from bodily fluids: Spheroidal beads present an exterior surface of a hydrophilic hydrogel, which is an isocyanate-functional polymer that is polymerized by urethane bonds and cross-linked by urethane and urea bonds. Sequestering agents present at the surface are covalently bound to isocyanate groups or to intermediate linkers that are so bound. These beads...

20060141047 - Methods and compositions for delivery of catecholic butanes for treatment of obesity: The present invention provides kits, methods and compositions for the treatment of obesity. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered...

20060141041 - Methods and compositions for the targeted delivery of biologically active agents: The present invention relates to a sustained release composition for the targeted delivery of biologically active agents to specific tissues and cells. The composition comprises microparticles containing a biocompatible polymer, a water-soluble polymer and a biologically active agent. In one embodiment, the biologically active agent is an antigen or an...

20060141046 - Particles for the delivery of active agents: Formulations of active agent particles of less than 100 microns in a droplet of dispersant, which is coated with a matrix of cationic and anionic polymers, are efficient vehicles for delivering active agents to tissues such as skin and mucosal membranes. Such formulations are able to deliver compounds to skin...

20060141044 - Pharmaceutical compositions based on diclofenac derivate: The present invention relates to particles comprising the drug 2-[2-(nitrooxy)ethoxy]ethyl{2-[(2,6-dichlorophenyl)amino]phenyl}acetate, optionally mixed with one or more surfactant(s) and to a new drug delivery composition comprising said particles optionally in combination with a second drug. Furthermore, the invention relates to processes for preparing said particles and drug delivery composition as well...

20060141049 - Triamcinolone compositions for intravitreal administration to treat ocular conditions: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps...

20060141053 - Pharmaceutical composition for improving palatability of drugs and process for preparation thereof: The present invention discloses compositions, comprising a lipid-polymer matrix to mask the bitter or unpleasant taste of the medicament. The lipid or a blend of lipids, are used in combination with the pH dependent polymer where the said polymer is acid soluble or swellable The process for the preparation of...

20060141054 - Metal coordinated compositions: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof....

20060141055 - Cardiac development promoting activity of perivitelline fluid of embryos of indian horseshoe crab, tachypleus gigas (muller): The present invention relates to a method for cardiac development activity in a subject comprising administering to the subject an appropriate amount of perivitelline fluid obtained from fertilized eggs of horseshoe crab....

20060141056 - Antimicrobial resin composition: A resin composition having excellent dispersibility, discoloration resistance and antimicrobial properties by blending a resin (A) with an antimicrobial agent (B) in which at least one kind of metal ion selected from the group consisting of silver, copper, zinc and tin is supported on zeolite, and an antimicrobial agent (C)...

20060141058 - Methods and compositions for weight management and mood enhancement: The present invention provides nutritional supplement compositions and processes for treatment using nutritional supplements that assist in weight management. One aspect of the invention comprises the inclusion in a single supplement constituent(s) that assist in reduction of a subject's cortisol level, thermogenic constituent(s), and constituent(s) that assist in stabilizing blood...

20060141057 - Methods of treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or...

20060141059 - Self-preserved ophthalmic pharmaceutical compositions containing tobramycin: Self-preserved, multi-dose ophthalmic compositions containing tobramycin are described. The compositions do not contain a conventional antimicrobial preservative, such as benzalkonium chloride. Rather, the compositions are self-preserved as a result of the inherent antimicrobial activity of tobramycin. The compositions preferably also contain either boric acid or, more preferably, a borate/polyol complex...

20060141060 - Molecular sieve materials having increased particle size for the formation of blood clots: A composition for clotting blood comprises a molecular sieve material. The molecular sieve material is in the form of particles, the particles having an average diameter of about 0.2 millimeters (mm) to about 10 mm. The molecular sieve material may be a zeolite, the zeolite being an aluminosilicate comprising at...

20060141067 - Anti-allergic herbal formulation: The invention provides a novel herbal preparation useful in treatment of allergy. Formulation(s) comprises of plant preparation or active component of plant extract together with conventional additives to form the oral dosage forms, which includes tablets, capsules and liquid dosage forms viz. syrup and suspension as anti-allergic. Formulation(s) comprises of...

20060141061 - Anti-arthritic herbal composition and method thereof: The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of...

20060141063 - Health promoting functional foods fortified with herbs: The present invention provides a novel herbal composition, which promotes the proven pharmacological activities such as anti-oxidant, anti-stress and adaptogenic activities. Composition(s) comprises of plant juices or extracts together with the conventional recipients to form paste/jelly/jam/cake/cream puff/chocolate forms fortified with plants like Mangifera indica, Evolvulus alsinoides, Withania somnifera and Asparagus...

20060141068 - Herbal formulation as memory enhancer in alzheimer condition: The invention provides a novel herbal formulation used to improve the memory and in treatment of senile and presenile dementia as a brain tonic. Formulation(s) comprises of alcoholic extract of Tinospora cordifolia, Centella asiatica, Withania somnifera, Mucuna pruriens and Curcuma longa. The formulation can be used as an emulsion or...

20060141065 -